Navigation Links
California's International Stem Cell Collaborations Must Be Based on Scientific Merit, Consumer Group Says
Date:6/18/2008

SANTA MONICA , Calif., June 18 /PRNewswire-USNewswire/ -- California's plans to join in cooperative stem cell research efforts with Canada and the Australian state of Victoria should be supported so long as they are based on scientific merit, not merely the glamour and glitz of playing on the world stage, said Consumer Watchdog.

The nonpartisan, nonprofit group, formerly The Foundation for Taxpayer and Consumer Rights, noted that the state's stem cell agency rightly pledged all its funding in the cooperative agreements would go to research in California, as provided by Proposition 71. Both Victoria and Canada have had substantial stem cell research efforts.

"If the collaborations are driven by the science, that's great," said John M. Simpson, Consumer Watchdog's Stem Cell Project Director. "If it's a matter of saying let's go international, just to play on the world stage, I would be dubious."

The California Institute for Regenerative Medicine (CIRM) in announcing the agreements today said that the first opportunity for the collaborative efforts will be with so-called disease team grants. These grants will fund research teams focusing on treating or curing specific diseases with stem cell techniques. A request for grant applications is expected in the fall. The multi-year grants worth millions of dollars are expected to be awarded next June.

"It's important that applicants for the disease team grants be judged completely on the scientific merit of their proposals," said Simpson. "Decisions cannot be twisted for geographic equity. I would hope that international collaborative efforts would rise to the top, but if they don't, so be it."

Consumer Watchdog also said CIRM must closely monitor and justify other costs that might be incurred because of international collaboration.

"I'm glad they've pledged that all the research funding will stay in California, as it must under the law," said Simpson, "but are there other costs associated with these plans? For instance, CIRM's proposed 2007-2008 budget includes a whopping 287 percent increase in travel, from $144,000 to $558,000. Increases of that magnitude demand scrutiny and their value must be adequately justified."

Proposition 71, which created CIRM, passed by 59 percent of Californians in 2004. Consumer Watchdog's Stem Cell Oversight and Accountability Project is working to ensure that California's landmark stem cell research program offers accessible and affordable cures and treatments to the taxpayers who have funded it. The program will sell $3 billion in bonds over a decade to fund stem cell research. Financing charges mean the project, the largest source of stem cell research funding in the world, will cost California taxpayers $6 billion.

Consumer Watchdog is a nonprofit, nonpartisan consumer advocacy group. For more information visit us on the web at: http://www.ConsumerWatchdog.org


'/>"/>
SOURCE Consumer Watchdog
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
2. Chindex International, Inc. Quantifies Fourth Quarter Charges
3. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
4. BioMS Medical to present at 2008 BIO International Convention
5. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
6. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
7. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
8. Interleukin Genetics to Present at 2008 BIO International Convention
9. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
10. New discoveries, new labs highlight international Canadian Light Source meeting
11. Georgia Showcases its Bioscience Leadership at 2008 Bio International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or the ... diseases, today announced it has issued a scientific white paper entitled “Results from ... series of commentaries from ProMIS’s scientific team offering insight into the Company’s product ...
(Date:2/22/2017)... Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... productivity traits and nutritional products, today announced their collaboration to achieve ... China to the United States ... ...
(Date:2/22/2017)... and SAN DIEGO , Feb. ... "Company") (OTCQB:CELZ) announced today expansion of its translational ... cell product through establishment of laboratory facilities in ... at the San Diego BioLabs facility, a biotechnology ... Novartis, and Sanofi. In November 2016, ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, ... health applications, announced a partnership with Redox, a leader in cloud-based healthcare integration ... clinical systems while keeping data secure in the cloud. , The digital health ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):